Global News

Astellas to close Urogenix, shift urology research to Japan

Monday, August 6, 2012 02:09 PM

Astellas Pharma has decided to close Urogenix, an Astellas subsidiary and Durham, N.C.-based research facility focusing on drug discovery in the field of urology.

More... »

Novartis, University of Penn. to expand use of personalized T cell therapy

Monday, August 6, 2012 12:44 PM

Aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Switzerland-based Novartis inked an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.

More... »

Saladax Biomedical expands collaboration with BMS

Monday, August 6, 2012 12:23 PM

Saladax Biomedical, a developer of novel diagnostic assays, has expanded its existing relationship with Bristol-Myers Squibb by entering into a Master Early Development Collaboration Agreement, which may include multiple feasibility studies and companion diagnostic development projects. 

More... »

Teva Canada completes sale of Mirabel facility to Halo Pharmaceutical

Monday, August 6, 2012 11:38 AM

Teva Canada, a healthcare solutions provider, has completed the sale of its Mirabel manufacturing facility in Montreal to Halo Pharmaceutical, a contract development and manufacturing organization (CDMO) based in Parsippany, N.J.

More... »

PharmaEngine, Nanobiotix enter into Asia-Pacific exclusive license and collaboration for NBTXR3

Monday, August 6, 2012 10:27 AM

PharmaEngine, a biopharmaceutical company based in Taiwan, inked an exclusive license and collaboration agreement with France-based nanomedicine company Nanobiotix for the development and commercialization of NBTXR3.

More... »

Prevention trial studies population 100% genetically predisposed to early-onset Alzheimer’s

Monday, August 6, 2012 07:00 AM

For the first time ever, an experimental drug is being tested to determine whether it can prevent Alzheimer’s disease in a population that has a 100% genetic predisposition for early onset of the disease. The study, to start next year, will be one of only a few being conducted to test prevention treatments for a genetically predestined disease.

More... »

Accenture to acquire Octagon Research Solutions

Friday, August 3, 2012 02:40 PM

Accenture, a global management consulting, technology services and outsourcing company, has agreed to acquire Octagon Research Solutions, a Wayne, Penn.-based provider of clinical and regulatory information management solutions and software for the pharmaceutical industry. Terms of the transaction were not disclosed.

More... »

Burrill & Company closes second Burrill Capital Fund IV

Friday, August 3, 2012 02:32 PM

Burrill & Company, a global life sciences financial services firm, announced a second close of its Burrill Capital Fund IV, bringing the aggregate capital commitments to $505 million.

More... »

Array BioPharma’s ARRY-797 meets primary endpoint in osteoarthritis study

Friday, August 3, 2012 12:41 PM

Boulder, Colo.-based Array BioPharma’s phase II study of ARRY-797 met its primary endpoint osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

More... »

PAREXEL appoints Larson as VP of evidence development

Friday, August 3, 2012 12:25 PM

PAREXEL Consulting, a business unit of PAREXEL International and a global consultancy serving the biopharmaceutical and medical device industries, has appointed Leanne R. Larson as vice president of evidence development, a newly created position.

More... »